Sana Biotechnology (SANA) Free Cash Flow (2020 - 2026)

Sana Biotechnology has reported Free Cash Flow for 7 years, with the latest figure at -$37.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 22.8% year-over-year to -$37.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.6 million (up 32.48% YoY) and the FY2025 annual result came in at -$144.8 million, up 35.13% from the prior year.
• Free Cash Flow retreated to -$37.7 million in Q1 2026 per SANA's latest filing, from -$33.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$29.5 million in Q3 2025 and troughed at -$81.4 million in Q1 2023.
• A 5-year average of -$56.5 million and a median of -$55.3 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 95.96% in 2022, then jumped 39.44% in 2025.
• Over 5 years, Free Cash Flow stood at -$74.9 million in 2022, then increased by 25.97% to -$55.4 million in 2023, then rose by 15.4% to -$46.9 million in 2024, then grew by 28.55% to -$33.5 million in 2025, then dropped by 12.39% to -$37.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$37.7 million, -$33.5 million, and -$29.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.